Pentraxin 3 is useful to differentiate infections from flares in patients with systemic lupus erythematosus who present systemic inflammatory response.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Works matching IS 09612033 AND DT 2019 AND VI 28 AND IP 10
Results: 14
1
2
Risk factors for bone loss in juvenile-onset systemic lupus erythematosus: a prospective study.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1224, doi. 10.1177/0961203319869467
- By:
- Publication type:
- Article
3
CORRIGENDUM: Lupus is associated with poorer outcomes after primary total hip arthroplasty.
- Published in:
- 2019
- Publication type:
- Correction Notice
4
Characteristics and safety of tattoos in patients with systemic lupus erythematosus.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1250, doi. 10.1177/0961203319867395
- By:
- Publication type:
- Article
5
Imbalance between CD8 + CD28 + and CD8 + CD28 – T-cell subsets and its clinical significance in patients with systemic lupus erythematosus.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1214, doi. 10.1177/0961203319867130
- By:
- Publication type:
- Article
6
Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1233, doi. 10.1177/0961203319867129
- By:
- Publication type:
- Article
7
Complex medical history of a patient with a compound heterozygous mutation in C1QC.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1255, doi. 10.1177/0961203319865029
- By:
- Publication type:
- Article
8
Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012–2016.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1273, doi. 10.1177/0961203319864168
- By:
- Publication type:
- Article
9
Treatment in thrombotic antiphospholipid syndrome: a review.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1181, doi. 10.1177/0961203319864163
- By:
- Publication type:
- Article
10
Patterns of medication use before, during and after pregnancy in women with systemic lupus erythematosus: a population-based cohort study.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1205, doi. 10.1177/0961203319863111
- By:
- Publication type:
- Article
11
Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1189, doi. 10.1177/0961203319862614
- By:
- Publication type:
- Article
12
Association of TNFSF4 rs1234315, rs2205960 polymorphisms and systemic lupus erythematosus susceptibility: a meta-analysis.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1197, doi. 10.1177/0961203319862610
- By:
- Publication type:
- Article
13
The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1261, doi. 10.1177/0961203319860198
- By:
- Publication type:
- Article
14
Aquaporin-4 IgG antibody-related disorders in patients with juvenile systemic lupus erythematosus.
- Published in:
- Lupus, 2019, v. 28, n. 10, p. 1243, doi. 10.1177/0961203319855125
- By:
- Publication type:
- Article